Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$37.39 USD
+0.51 (1.38%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $37.38 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Company Summary
Headquartered in Waltham, MA, Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, that work through the inhibition of the complement system, especially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
In May 2021, the Food and Drug Administration (FDA) approved Empaveli (pegcetacoplan) for treating Paroxysmal Nocturnal Hemoglobinuria (PNH). The drug recorded sales of $91 million in 2023. The European Commission has approved Aspaveli (pegcetacoplan) for the treatment of adult patients with PNH who are anemic following treatment with a C5 inhibitor for at least ...
Company Summary
Headquartered in Waltham, MA, Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, that work through the inhibition of the complement system, especially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
In May 2021, the Food and Drug Administration (FDA) approved Empaveli (pegcetacoplan) for treating Paroxysmal Nocturnal Hemoglobinuria (PNH). The drug recorded sales of $91 million in 2023. The European Commission has approved Aspaveli (pegcetacoplan) for the treatment of adult patients with PNH who are anemic following treatment with a C5 inhibitor for at least three months.
In February 2023, the FDA approved pegcetacoplan injection, the first and only approved therapy for geographic atrophy (GA). The drug is marketed under the brand name, Syfovre. It is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. Syfovre is approved in the United States for treating geographic atrophy secondary to age-related macular degeneration.
The company has a development funding agreement, with SFJ Pharmaceuticals Group (SFJ), under which the latter agreed to provide funding to the former to support the development of Empaveli for PNH. Under the agreement, SFJ paid $60 million following the signing of the agreement. SFJ will also pay an additional $60 million in three equal installments on the achievement of specified development milestones concerning the latter’s phase III program for Empaveli in PNH.
For 2023, Apellis generated total revenues of $396.6 million compared with $75.4 million recorded in 2022.
General Information
Apellis Pharmaceuticals, Inc
100 FIFTH AVENUE
WALTHAM, MA 02451
Phone: 617-977-5700
Fax: NA
Email: meredith.kaya@apellis.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 8/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.31 |
Current Year EPS Consensus Estimate | -1.07 |
Estimated Long-Term EPS Growth Rate | 38.30 |
Earnings Date | 8/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 36.88 |
52 Week High | 73.80 |
52 Week Low | 19.83 |
Beta | 0.88 |
20 Day Moving Average | 1,434,791.50 |
Target Price Consensus | 74.76 |
4 Week | -8.71 |
12 Week | -16.54 |
YTD | -38.39 |
4 Week | -10.13 |
12 Week | -24.35 |
YTD | -47.10 |
Shares Outstanding (millions) | 121.37 |
Market Capitalization (millions) | 4,475.96 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 65.38% |
vs. Previous Quarter | 26.03% |
vs. Previous Year | 284.26% |
vs. Previous Quarter | 17.73% |
Price/Book | 16.77 |
Price/Cash Flow | NA |
Price / Sales | 8.54 |
6/30/24 | NA |
3/31/24 | -160.77 |
12/31/23 | -178.60 |
6/30/24 | NA |
3/31/24 | -49.79 |
12/31/23 | -60.41 |
6/30/24 | NA |
3/31/24 | 3.77 |
12/31/23 | 3.10 |
6/30/24 | NA |
3/31/24 | 3.02 |
12/31/23 | 2.50 |
6/30/24 | NA |
3/31/24 | -79.67 |
12/31/23 | -133.34 |
6/30/24 | NA |
3/31/24 | -79.67 |
12/31/23 | -133.34 |
6/30/24 | NA |
3/31/24 | -79.24 |
12/31/23 | -132.76 |
6/30/24 | NA |
3/31/24 | 2.20 |
12/31/23 | 1.64 |
6/30/24 | NA |
3/31/24 | 0.56 |
12/31/23 | 0.54 |
6/30/24 | NA |
3/31/24 | 0.35 |
12/31/23 | 0.48 |
6/30/24 | NA |
3/31/24 | 25.88 |
12/31/23 | 32.35 |